SURPASS–CVOT
The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes
- Stage
- klaar
- Medicine
- Tirzepatide
- Population
- Diabetes Mellitus
- Phase
- III
- First Patient In
- 23 September 2020
- Last Patient In
- 31 August 2021
- Last Patient Last Visit
- 1 May 2025
National Lead
dr. A.F.M. Kuijper
Cardioloog
Study Director
dr. F.J.F. Broeyer
Cardioloog
Office Contact
